Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, Corvaja C, Arpino G, Del Mastro L, De Placido S, De Laurentiis M, Cristofanilli M, Puglisi F. Buono G, et al. Among authors: puglisi f. Cancer Treat Rev. 2019 Feb;73:73-83. doi: 10.1016/j.ctrv.2019.01.004. Epub 2019 Jan 11. Cancer Treat Rev. 2019. PMID: 30682661 Free article. Review.
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside.
Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F. Basile D, et al. Among authors: puglisi f. Cancers (Basel). 2019 Jun 20;11(6):857. doi: 10.3390/cancers11060857. Cancers (Basel). 2019. PMID: 31226812 Free PMC article. Review.
Hype or hope? The strange case of platinum salts' renaissance in breast cancer.
Corvaja C, Garutti M, Gerratana L, Pelizzari G, Puglisi F. Corvaja C, et al. Among authors: puglisi f. Expert Rev Anticancer Ther. 2019 Dec;19(12):1005-1008. doi: 10.1080/14737140.2019.1699066. Epub 2019 Dec 2. Expert Rev Anticancer Ther. 2019. PMID: 31775005 No abstract available.
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer.
Basile D, Garattini SK, Corvaja C, Montico M, Cortiula F, Pelizzari G, Gerratana L, Audisio M, Lisanti C, Fanotto V, Ongaro E, Iacono D, Cardellino GG, Foltran L, Pella N, Buonadonna A, Aprile G, Di Maio M, Fasola G, Puglisi F. Basile D, et al. Among authors: puglisi f. Oncologist. 2020 Aug;25(8):661-668. doi: 10.1634/theoncologist.2019-0780. Epub 2020 Mar 23. Oncologist. 2020. PMID: 32202020 Free PMC article.
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer.
Garattini SK, Bonotto M, Porcu L, Ongaro E, Gerratana L, Basile D, Parnofiello A, Pelizzari G, Cortiula F, Corvaja C, Casagrande M, Cardellino GG, Buonadonna A, Aprile G, Puglisi F, Fasola G, Pella N. Garattini SK, et al. Among authors: puglisi f. Future Oncol. 2020 Nov;16(32):2645-2660. doi: 10.2217/fon-2020-0270. Epub 2020 Aug 10. Future Oncol. 2020. PMID: 32776795
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer.
Gerratana L, Basile D, Franzoni A, Allegri L, Viotto D, Corvaja C, Bortot L, Bertoli E, Buriolla S, Targato G, Da Ros L, Russo S, Bonotto M, Belletti B, Baldassarre G, Damante G, Puglisi F. Gerratana L, et al. Among authors: puglisi f. Front Oncol. 2020 Sep 18;10:550185. doi: 10.3389/fonc.2020.550185. eCollection 2020. Front Oncol. 2020. PMID: 33072577 Free PMC article.
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Vernieri C, et al. Among authors: puglisi f. Clin Cancer Res. 2021 Jun 15;27(12):3443-3455. doi: 10.1158/1078-0432.CCR-20-4928. Epub 2021 Mar 30. Clin Cancer Res. 2021. PMID: 33785482 Free article.
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Basile D, Gerratana L, Corvaja C, Pelizzari G, Franceschin G, Bertoli E, Palmero L, Zara D, Alberti M, Buriolla S, Da Ros L, Bonotto M, Mansutti M, Spazzapan S, Cinausero M, Minisini AM, Fasola G, Puglisi F. Basile D, et al. Among authors: puglisi f. Breast. 2021 Jun;57:104-112. doi: 10.1016/j.breast.2021.02.015. Epub 2021 Mar 12. Breast. 2021. PMID: 33812267 Free PMC article.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Among authors: puglisi f. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
450 results